TW263498B - - Google Patents

Info

Publication number
TW263498B
TW263498B TW083110229A TW83110229A TW263498B TW 263498 B TW263498 B TW 263498B TW 083110229 A TW083110229 A TW 083110229A TW 83110229 A TW83110229 A TW 83110229A TW 263498 B TW263498 B TW 263498B
Authority
TW
Taiwan
Prior art keywords
stands
optionally substituted
ring
hydrogen atom
hydrocarbon residue
Prior art date
Application number
TW083110229A
Other languages
English (en)
Chinese (zh)
Original Assignee
Takeda Pharm Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharm Industry Co Ltd filed Critical Takeda Pharm Industry Co Ltd
Application granted granted Critical
Publication of TW263498B publication Critical patent/TW263498B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW083110229A 1993-11-10 1994-11-05 TW263498B (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP28117893 1993-11-10
JP33748893 1993-12-28
JP3363794 1994-03-03
JP13855194 1994-06-21

Publications (1)

Publication Number Publication Date
TW263498B true TW263498B (enExample) 1995-11-21

Family

ID=27459814

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083110229A TW263498B (enExample) 1993-11-10 1994-11-05

Country Status (16)

Country Link
US (1) US5585385A (enExample)
EP (1) EP0652218B1 (enExample)
KR (1) KR950014108A (enExample)
CN (1) CN1052004C (enExample)
AT (1) ATE203024T1 (enExample)
AU (1) AU678295B2 (enExample)
BR (1) BR9404403A (enExample)
CA (1) CA2135440A1 (enExample)
DE (1) DE69427675T2 (enExample)
FI (1) FI945281L (enExample)
HU (1) HUT68810A (enExample)
IL (1) IL111590A0 (enExample)
NO (1) NO301764B1 (enExample)
NZ (1) NZ264887A (enExample)
RU (1) RU2135471C1 (enExample)
TW (1) TW263498B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770590A (en) * 1995-03-24 1998-06-23 Takeda Chemical Industries, Ltd. Cyclic compounds, their prudiction and use
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
US6087373A (en) * 1997-09-23 2000-07-11 Merck & Co., Inc. Thrombin inhibitors
AU740447B2 (en) * 1997-09-23 2001-11-01 Merck & Co., Inc. Thrombin inhibitors
US6727258B2 (en) * 1997-10-29 2004-04-27 King Pharmaceutical Research & Development, Inc. Allosteric adenosine receptor modulators
US6323214B1 (en) 1997-10-29 2001-11-27 Medco Research, Inc Allosteric adenosine receptor modulators
US5939432A (en) * 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
WO2000012503A1 (en) * 1998-08-26 2000-03-09 Tanabe Seiyaku Co., Ltd. Naphthyridine derivatives and process for the preparation thereof
AU6228499A (en) * 1998-10-22 2000-05-08 Akzo Nobel N.V. Tetrahydropyridopyridine derivatives and intermediates for producing the same
US6239132B1 (en) 1999-04-23 2001-05-29 Merck & Co., Inc. Thrombin inhibitors
CA2374654A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Thrombin inhibitors
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
EP1457493A4 (en) 2001-12-10 2005-11-30 Kyorin Seiyaku Kk CONDENSED, BICYCLIC PYRIDINE DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONISTS
KR100887471B1 (ko) * 2002-01-18 2009-03-10 교린 세이야꾸 가부시키 가이샤 축합 바이사이클릭 피리미딘 유도체
US7402595B2 (en) * 2002-02-13 2008-07-22 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2003077857A2 (en) * 2002-03-15 2003-09-25 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors
US7026309B2 (en) 2002-03-26 2006-04-11 Kyorin Pharmaceutical Co., Ltd. Fused bicyclic pyridine derivative as tachykinin receptor antagonist
AU2003296984A1 (en) 2002-12-13 2004-07-09 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
RU2229475C1 (ru) * 2003-03-06 2004-05-27 ООО "Исследовательский институт химического разнообразия 6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
US7781457B2 (en) 2003-09-23 2010-08-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
CA2539760C (en) 2003-09-23 2011-01-25 Merck & Co., Inc. Quinoline potassium channel inhibitors
WO2005068427A1 (ja) * 2004-01-14 2005-07-28 Takeda Pharmaceutical Company Limited カルボキサミド誘導体およびその用途
KR100781704B1 (ko) * 2005-04-20 2007-12-03 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR056048A1 (es) * 2005-09-01 2007-09-12 Tanabe Seiyaku Co Compuesto tiomorfolina y procedimiento para preparar el mismo
RU2359962C1 (ru) * 2007-12-13 2009-06-27 Общество с ограниченной ответственностью "Консорциум-ПИК" (ООО "Консорциум-ПИК") Нейротропное средство и способ его получения
RU2429230C1 (ru) * 2010-05-27 2011-09-20 Учреждение Российской академии наук Институт проблем химико-энергетических технологий Сибирского отделения РАН (ИПХЭТ СО РАН) Способ получения n-метил-4-бензилкарбамидопиридиния йодида
CA2828456C (en) * 2011-03-03 2021-05-04 Zalicus Pharmaceuticals Ltd. N-benzl-amino-carboxamide inhibitors of the sodium channel
CN102358730A (zh) * 2011-08-24 2012-02-22 济南赛文医药技术有限公司 一种小分子mek蛋白激酶抑制剂
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US9663533B2 (en) 2012-11-14 2017-05-30 Glaxosmithkline Llc Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors
HK1223364A1 (zh) 2013-06-28 2017-07-28 Abbvie Inc. 布罗莫结构域抑制剂
RU2770050C2 (ru) * 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
AU2017251537B2 (en) 2016-04-15 2020-10-08 Abbvie Inc. Bromodomain inhibitors
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
EP4327779A3 (en) 2019-04-26 2024-05-08 AMO Ireland System and method
KR20220145844A (ko) 2020-02-25 2022-10-31 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 아토피 피부염의 개선된 치료
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2021233800A1 (en) 2020-05-20 2021-11-25 Merck Patent Gmbh Azacoumarin and azathiocoumarin derivatives for use in optically active devices
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
IL75987A (en) * 1984-08-25 1991-07-18 Goedecke Ag Tri-and tetrasubstituted-1,4-dihydro-1,6-naphthyridine-3-carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IE892088L (en) * 1988-07-12 1990-01-12 William Henry Deryk Morris Quinoline derivatives, their production and use
TW205037B (enExample) * 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
FR2654725B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
DE69106499T2 (de) * 1990-02-10 1995-06-29 Takeda Chemical Industries, Ltd., Osaka Chromenderivate, deren herstellung und verwendung.
US5143919A (en) * 1990-08-17 1992-09-01 Takeda Chemical Industries, Ltd. Thienopyridine derivatives and their pharmaceutical use
DE69110828T2 (de) * 1990-10-16 1995-11-30 Takeda Chemical Industries Ltd Heterozyklische Aminderivate, deren Herstellung und deren Verwendung.
TW241258B (enExample) * 1992-04-15 1995-02-21 Takeda Pharm Industry Co Ltd
DE4215587A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone
DE4215588A1 (de) * 1992-05-12 1993-11-18 Bayer Ag Biphenylmethyl-substituierte Pyridone
DE69315920T2 (de) * 1992-09-04 1998-06-10 Takeda Chemical Industries Ltd Kondensierte heterozyklische Verbindungen, deren Herstellung und Verwendung
JPH06298757A (ja) * 1993-04-15 1994-10-25 Kissei Pharmaceut Co Ltd ピペリジノ−3,4−ジヒドロカルボスチリル誘導体

Also Published As

Publication number Publication date
AU7773894A (en) 1995-05-18
BR9404403A (pt) 1995-07-18
HU9403230D0 (en) 1995-01-30
RU2135471C1 (ru) 1999-08-27
KR950014108A (ko) 1995-06-15
FI945281A0 (fi) 1994-11-09
FI945281A7 (fi) 1995-05-11
ATE203024T1 (de) 2001-07-15
IL111590A0 (en) 1995-01-24
EP0652218B1 (en) 2001-07-11
HUT68810A (en) 1995-05-19
DE69427675T2 (de) 2002-05-16
CN1107476A (zh) 1995-08-30
DE69427675D1 (de) 2001-08-16
RU94040174A (ru) 1996-10-10
NO944252D0 (no) 1994-11-08
CN1052004C (zh) 2000-05-03
NO301764B1 (no) 1997-12-08
EP0652218A1 (en) 1995-05-10
AU678295B2 (en) 1997-05-22
CA2135440A1 (en) 1995-05-11
NO944252L (no) 1995-05-11
US5585385A (en) 1996-12-17
FI945281L (fi) 1995-05-11
NZ264887A (en) 1996-12-20

Similar Documents

Publication Publication Date Title
HU9403230D0 (en) Heterocyclic compounds, their production and use
AU2001230564A1 (en) Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2352495A (en) Condensed heterocyclic compounds, their production and use as gnrh antagonists
IL142649A0 (en) Azole derivatives
NO940550L (enExample)
WO2001077107A8 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors
AU2454295A (en) Novel fused indan derivative and pharmaceutically acceptablesalt thereof
AU9281198A (en) Benzofuran derivatives
WO1992019210A3 (en) Serotinin reuptake inhibitors for s.p.e.c.t imaging
AU4223696A (en) Preventive or alleviative agent for hypertension or medical symptoms caused thereby
MXPA04002569A (es) H6,7-dihidro-5h-pirazolo[1,2-a]pirazol-1-onas espirociclicas que controlan citocinas inflamatorias.
AU7708394A (en) Indoline compound and 5-ht3 receptor antagonist containing the same as active ingredient
AU670675B2 (en) Morpholine derivative
AU4632996A (en) Use of vinpocetine derivatives for inhibiting production or secretion of amyloid beta protein
WO1998003508A3 (de) Substituierte triazoloazinsulfonamide und ihre verwendung als planzenbehandlungsmittel
EP0680960A4 (en) IMIDAZOLE CONNECTION.
EP0394471A4 (en) Thienocycloheptapyridazine compounds and medicinal uses thereof
AU6470696A (en) Penicillaminamide derivatives
EP0579836A4 (enExample)
TW222273B (enExample)
EP1103548A4 (en) TRIAZOLONE DERIVATIVES, THEIR USE AND INTERMEDIATE CONNECTION THEREFOR
EP0924204A4 (en) 2-PHENYLMORPHOLIN-5-ON DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME
WO1999059996A8 (en) Antitumour 1,5-diazaanthraquinones
DE69706950D1 (de) Furoindolizine
AU7332996A (en) Therapeutics for thrombocytopenia